APstem News

Publications

Treatment of Full-Thickness Skin Wounds with Blood-Derived CD34+ Precursor Cells Enhances Healing with Hair Follicle Regeneration

Advances in Wound Care

Expansion and Hepatic Differentiation of Adult Blood-Derived CD34+ Progenitor Cells and Promotion of Liver Regeneration After Acute Injury

Stem Cell Translational Medicine

Peripheral Blood‐Derived Mesenchymal Stem Cells: Candidate Cells Responsible for Healing Critical‐Sized Calvarial Bone Defects

Stem Cell Translational Medicine

News & Media

APstem Therapeutics LOGO.png

In 2024, APstem presented poster entitled “REVERSING TYPE I DIABETES IN NOD MICE BY HUMAN HIGH-PLASTICITY STEM CELLS” in ISSCR Copenhagen International Symposium, “PSC-Derived Cell Therapies: Clinical Advances, NextGen Technologies, and the Path to Success.”

In 2023, APstem had a pre-IND meeting with the FDA regarding AP-Skin-01, an “off-the-shelf” allogeneic stem cell product for the treatment of diabetic ulcers.

In 2019, APstem presented poster entitled “TREATMENT OF DIABETIC ULCERS WITH ACTIVATED ADULT STEM/PRECURSOR CELLS” in ISSCR Toronto International Symposium, “From Stem Cell Biology to New Therapies.”

APstem Therapeutics LOGO.png

APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an “Off-the-Shelf” Allogeneic Stem Cell Product for the Treatment of Diabetic Ulcers

StartX.jpg

Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force

sv+biz+logo.jpg

The Funded: StartX Extends COVID-19 Demo Day

Abc-news-logo.png

Inside the Silicon Valley ‘brain trust’ taking aim at COVID-19

  • Presented in 2018 JPM US-China
    Healthcare Roadshow

  • Poster presentation in ISSCR International Symposium, Toronto 2019